• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by PureTech Health plc

    2/12/25 5:27:53 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRTC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Puretech Health Plc

    (Name of Issuer)


    Ordinary Shares

    (Title of Class of Securities)


    G7297M101

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G7297M101


    1Names of Reporting Persons

    Citigroup Global Markets Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,703,044.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,703,044.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,703,044.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.5 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP No.
    G7297M101


    1Names of Reporting Persons

    Citigroup Global Markets Holdings Bahamas Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BAHAMAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,703,044.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,703,044.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,703,044.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.5 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP No.
    G7297M101


    1Names of Reporting Persons

    Citigroup Financial Products Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,703,044.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,703,044.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,703,044.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.5 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    G7297M101


    1Names of Reporting Persons

    Citigroup Global Markets Holdings Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,703,044.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,703,044.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,703,044.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.5 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    G7297M101


    1Names of Reporting Persons

    Citigroup Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,703,044.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,703,044.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,703,044.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.5 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Puretech Health Plc
    (b)Address of issuer's principal executive offices:

    6 Tide Street, Suite 400, Boston, MA 02210
    Item 2. 
    (a)Name of person filing:

    Citigroup Global Markets Limited ("CGML"), Citigroup Global Markets Holdings Bahamas Limited ("CGMHBL"), Citigroup Financial Products Inc. ("CFP"), Citigroup Global Markets Holdings Inc. ("CGM Holdings"), Citigroup Inc. ("Citigroup").
    (b)Address or principal business office or, if none, residence:

    CGML: 25 Canary Square, London GB E145LB. CGMHBL: Ocean Center, Montagu Foreshore, East Bay Street Nassau, New Providence Bahamas 19084. CFP, CGM Holdings and Citigroup: 388 Greenwich Street, New York, NY 10013.
    (c)Citizenship:

    CGML is chartered and headquartered in England. CGMHBL is chartered and headquartered in the Bahamas. CGM Holdings is a New York corporation. CFP and Citigroup are Delaware corporations.
    (d)Title of class of securities:

    Ordinary Shares
    (e)CUSIP No.:

    G7297M101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Foreign Financial Institution
    Item 4.Ownership
    (a)Amount beneficially owned:

    10,703,044
    (b)Percent of class:

    4.5  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    10,703,044

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    10,703,044

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    CGMHBL is the sole stockholder of CGML. CFP is the sole stockholder of CGMHBL. CGM Holdings is the sole stockholder of CFP. Citigroup is the sole stockholder of CGM Holdings.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Citigroup Global Markets Limited
     
    Signature:Simon Cumming
    Name/Title:Assistant Company Secretary
    Date:02/12/2025
     
    Citigroup Global Markets Holdings Bahamas Limited
     
    Signature:David Graham
    Name/Title:UK Controller
    Date:02/12/2025
     
    Citigroup Financial Products Inc.
     
    Signature:Ronny Ostrow
    Name/Title:Assistant Secretary
    Date:02/12/2025
     
    Citigroup Global Markets Holdings Inc.
     
    Signature:Ronny Ostrow
    Name/Title:Assistant Secretary
    Date:02/12/2025
     
    Citigroup Inc.
     
    Signature:Ronny Ostrow
    Name/Title:Assistant Secretary
    Date:02/12/2025
    Get the next $PRTC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRTC

    DatePrice TargetRatingAnalyst
    9/9/2024$58.00 → $45.00Outperform
    Leerink Partners
    1/7/2022$76.00 → $70.00Outperform
    SVB Leerink
    8/25/2021$74.00 → $76.00Outperform
    SVB Leerink
    More analyst ratings

    $PRTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PureTech Health: Notice of Half-Yearly Results

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended June 30, 2025, on Thursday, August 28, 2025. A presentation and conference call for analysts and shareholders will take place at 9:00am EDT / 2:00pm BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep port

    8/18/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

    VE202 was well tolerated, with no reports of treatment-related serious adverse events Additional analyses from COLLECTiVE202 to be shared in upcoming scientific forums Vedanta to focus resources on ongoing Phase 3 RESTORATiVE303 registrational study of VE303 in recurrent Clostridioides difficile infection PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech"), noted that its Founded Entity, Vedanta Biosciences, ("Vedanta") a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced that its candidate VE202 did not meet the primary endpoint in the Phase 2 COLLECTiVE202 study for the treatment of patients

    8/13/25 12:16:00 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases

    Former Teva North America CEO Sven Dethlefs, PhD, to lead Celea PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced the launch of a new Founded Entity Celea Therapeutics ("Celea"). Celea's mission is to deliver therapies that transform the lives of people with serious respiratory diseases. Its lead program, deupirfenidone (LYT-100), is a Phase 3-ready therapeutic candidate that holds promise across multiple fibrotic and inflammatory lung conditions and is initially being advanced for the treatment of idiopathic pulmonary fibrosis (IPF),

    8/12/25 7:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners resumed coverage on PureTech Health plc with a new price target

    Leerink Partners resumed coverage of PureTech Health plc with a rating of Outperform and set a new price target of $45.00 from $58.00 previously

    9/9/24 7:42:36 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Leerink reiterated coverage on PureTech Health with a new price target

    SVB Leerink reiterated coverage of PureTech Health with a rating of Outperform and set a new price target of $70.00 from $76.00 previously

    1/7/22 4:34:06 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Leerink reiterated coverage on PureTech Health with a new price target

    SVB Leerink reiterated coverage of PureTech Health with a rating of Outperform and set a new price target of $76.00 from $74.00 previously

    8/25/21 4:40:14 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by PureTech Health plc

    SCHEDULE 13G - PureTech Health plc (0001782999) (Subject)

    8/11/25 1:05:29 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PureTech Health plc

    6-K - PureTech Health plc (0001782999) (Filer)

    7/16/25 6:30:13 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PureTech Health plc

    6-K - PureTech Health plc (0001782999) (Filer)

    7/8/25 4:15:37 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Leadership Updates

    Live Leadership Updates

    View All

    PureTech Announces Leadership Transition

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announces that Bharatt Chowrira, PhD, JD, has stepped down today from his role as Chief Executive Officer (CEO) and as a member of the Board of Directors. The Board of Directors has appointed Robert Lyne as Interim CEO with effect from today. Mr. Lyne joined PureTech as Chief Portfolio Officer in January 2024 and is an experienced leader of UK-listed life science innovation and venture capital companies, having previously served as CEO of Arix Bioscience plc. He will continue to work closely with PureTe

    7/16/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Appoints Peel Hunt as Joint UK Corporate Broker

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), is pleased to announce that it has appointed Peel Hunt as Joint UK Corporate Broker alongside UBS. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeut

    4/9/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    $PRTC
    Financials

    Live finance-specific insights

    View All

    PureTech Health: Notice of Half-Yearly Results

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended June 30, 2025, on Thursday, August 28, 2025. A presentation and conference call for analysts and shareholders will take place at 9:00am EDT / 2:00pm BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep port

    8/18/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Health: Notice of Results

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2024, on Wednesday, April 30, 2025. A presentation and conference call to discuss the results will take place at 9:00 AM EDT / 2:00 PM BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a b

    4/23/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

    Dose-ranging trial evaluated deupirfenidone 550 mg three times a day (TID) (approximately equivalent exposure to pirfenidone 801 mg TID1) and deupirfenidone 825 mg TID and successfully demonstrated dose-dependent response Decline in lung function seen with deupirfenidone 825 mg TID as a monotherapy was -21.5 mL; natural lung function decline expected in healthy adults >60 years is ~-15 to ~-25 mL2; decline in lung function with pirfenidone 801 mg TID was -51.6 mL Deupirfenidone 825 mg TID showed strong, consistent and durable efficacy with a treatment effect versus placebo of 80.9% with favorable tolerability, while pirfenidone 801 mg TID had a 54.1% treatment effect versus placebo De

    12/16/24 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PureTech Health plc

    SC 13G - PureTech Health plc (0001782999) (Subject)

    11/12/24 1:29:13 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PureTech Health plc

    SC 13G/A - PureTech Health plc (0001782999) (Subject)

    11/7/24 9:47:57 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by PureTech Health plc (Amendment)

    SC 13G/A - PureTech Health plc (0001782999) (Subject)

    2/12/24 4:48:30 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care